SynthesisHeart failure reviews2021
Prognostic significance of T1 mapping parameters in heart failure with preserved ejection fraction: a systematic review.
Synthesis in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction.Scientific reports · 2021Trial
- Technical challenges in establishing local native T1 reference ranges in cardiac MRI: a critical review.Insights into imaging · 2026Review
- Atrial fibrillation is linked to increased left ventricular fibrosis and inflammation measured by CMR with prognostic implications.The international journal of cardiovascular imaging · 2026Article
- Cardiac Magnetic Resonance Imaging in Asia: 2025 Status Update.Korean journal of radiology · 2025Article
- One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes.International journal of molecular sciences · 2025Review
- Native T1 adds independent value for cardiovascular risk assessment beyond global longitudinal strain in an all-comers real-world clinical patient population.European heart journal open · 2025Article
- Recent Progress of Cardiac MRI for Nuclear Medicine Professionals.Nuclear medicine and molecular imaging · 2024Review
- Functional assessment and influencing factors after staged functional training in patients with ankle fractures.World journal of clinical cases · 2024Article
- CMR-based cardiac phenotyping in different forms of heart failure.The international journal of cardiovascular imaging · 2024Article
- Distinguishing heart failure subtypes: the diagnostic power of different cardiac magnetic resonance imaging parameters.Frontiers in cardiovascular medicine · 2024Article
- Differentiating the Prognostic Determinants of Myocardial Steatosis for Heart Failure With Preserved Ejection Fraction by Cardiac Magnetic Resonance Imaging.Journal of the American Heart Association · 2023Article
- Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Current heart failure reports · 2022Review
- Myocardial fibrosis in patients with a history of Kawasaki disease.International journal of cardiology. Heart & vasculature · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for almost one-half of all heart failure (HF) patients and continues to increase in prevalence. While mortality with heart failure with reduced ejection fraction (HFrEF) has decreased over the past few decades with use of evidence-based HFrEF therapy, mortality related to heart failure with HFpEF has not changed significantly over the same time period. The combination of poor prognosis and lack of effective treatment options creates a pressing need for novel strategies for better patient characterization. We conducted a systematic review to evaluate the prognostic value of cardiac magnetic resonance (CMR)-derived T1 relaxation time and extracellular volume fraction (ECV) in HFpEF patients. PubMed, Embase, and Cochrane Central were searched for relevant studies. The primary outcomes of interest were hospitalization for HF and all-cause mortality. Five studies with 2741 patients were included. Four studies reported correlation of outcomes with ECV, 2 studies reported correlation of outcomes with native T1 time, and 1 study reported correlation of outcomes with post-contrast T1 time. All five studies showed significant correlation of CMR-derived parameters with adverse outcomes including event-free survival to cardiac event, all cause, and cardiac mortality. CMR-determined ECV is strongly correlated with adverse outcomes in HFpEF cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.